UCal granted wide-ranging CRISPR rights, but future patent landscape remains uncertain

Despite doubts, the University of California has been awarded fundamental rights to Cas9 gene-editing technology. But validity challenges could be on the way, experts say.

Get unlimited access to all IAM content